Merge Technologies Incorporated Adopts New Corporate Name. New name, Merge eFilm blends reputation for PACS, integration expertise, clinical proficiency and image visualization.
Milwaukee, WI, September 5, 2002

Milwaukee, WI, September 5, 2002 - Merge Technologies Incorporated, which recently acquired eFilm Medical Inc., today announced the change of its corporate name to Merge eFilm. Merge eFilm will continue to trade on Nasdaq under its current ticker symbol MRGE.

"The goal of the name change is to communicate a simple and clear message to the market. Merge eFilm is a new company with broader capabilities where the integration, service and radiology workflow capabilities of Merge are combined with the image visualization and clinical expertise of eFilm. We are already seeing sales, customer service and product innovation synergies and the change in our name projects a more complete picture of our future in the healthcare image and information market," stated Rich Linden, Merge eFilm President and CEO.

Press Contact
Attn: Beth Frost-Johnson Merge Healthcare 6737 West Washington St. Suite 2250 Milwaukee, WI 53214		Phone: 1-(414) 977-4254
Email Address: marketing@merge.com
Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, the forward-looking statements based on a number of factors, including, but not limited to, the uncertainty created by, the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company’s senior management; costs, risks and effects of the investigation by the Audit Committee of the Board of Directors; the impact of the restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; costs, risks and effects of legal proceedings and investigations, including the informal, non-public inquiry being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances, or for any other reason.